Drugs / HRS8807
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04993430 | Oct 2021 → Dec 2026 expected | breast carcinoma by gene expression profile | Shanghai Hengrui Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS8807 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04993430 ↗ |